Trials / Completed
CompletedNCT01335958
Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
A Phase I, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 77 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I, multi-center, open-label, dose-escalation study of DMUC5754A administered as a single agent by intravenous (IV) infusion to patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DMUC5754A | Escalating intravenous dose |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2014-02-01
- Completion
- 2014-02-01
- First posted
- 2011-04-15
- Last updated
- 2016-11-02
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01335958. Inclusion in this directory is not an endorsement.